Recent Updates
Recently added Catalysts
BMRN Positive Sentiment

BioMarin to Participate in Upcoming Investor Conferences

Key Takeaway: BioMarin Pharmaceutical Inc. announced its participation in several investor conferences in November. The Stifel Healthcare Conference will take place on November 11, followed by the UBS Global Biopharma Conference on November 16, and the Jefferies Global Healthcare Conference on November 17. Live audio webcasts will be available for each presentation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Management will present at multiple investor conferences.
  • BioMarin has a strong clinical and preclinical pipeline.
  • The company has a proven track record of innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
7.1%
average across 10 past catalysts
Lead asset
N-acetylgalactosamine 4-sulfatase
Phase 3 · Mucopolysaccharidosis VI

Full Press Release Details

• Stifel Healthcare Conference, November 11 at 3:20 pm EST
• UBS Global Biopharma Conference, November 16 at 9:20 am GMT
• Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT
SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803

Frequently Asked Questions

When will BioMarin present at the Stifel Healthcare Conference?

BioMarin will present on November 11 at 3:20 pm EST.

What is the date for the UBS Global Biopharma Conference?

The UBS Global Biopharma Conference is on November 16 at 9:20 am GMT.

How can I access the webcasts of the presentations?

The webcasts will be available live on BioMarin's investor website.

What type of company is BioMarin?

BioMarin is a biotechnology company focused on rare genetic diseases.

Last updated: Nov 4, 2026